Obesity and cancer risk: the role of the insulin-IGF axis

Trends in Endocrinology and Metabolism

Volumn 17, Issue 8, 2006, Pages 328-336

  Renehan, Andrew G ^a   Frystyk, Jan ^b   Flyvbjerg, Allan ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; INSULIN; SOMATOMEDIN;

CALORIC RESTRICTION; CANCER RISK; CELL ACTIVITY; DISEASE ASSOCIATION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CROSS-SECTIONAL STUDIES; HUMANS; INSULIN; MODELS, ANIMAL; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEOPLASMS; OBESITY; RISK; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 33748703827     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2006.08.006     Document Type: Review

References (70)

1. Renehan A.G., and Howell A. Preventing cancer, cardiovascular disease, and diabetes. Lancet 365 (2005) 1449-1451
2. IARC (2002) International Agency for Research in Cancer. Weight control and physical activity. (Vainio, H. and Bianchini, F. eds), IARC Press
3. LeRoith D., and Roberts Jr. C.T. The insulin-like growth factor system and cancer. Cancer Lett. 195 (2003) 127-137
4. Khandwala H.M., et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21 (2000) 215-244
5. Renehan, A.G. (2006) IGFs and cancer. www.christie.man.ac.uk/proinfo/departments/surgery/default.htm
6. Frasca F., et al. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis. 17 (2003) 73-89
7. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk?. Cancer Epidemiol. Biomarkers Prev. 3 (1994) 687-695
8. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 6 (1995) 164-179
9. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm. Metab. Res. 35 (2003) 694-704
10. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4 (2004) 579-591
11. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 14 (2004) 337-375
12. Frystyk J., et al. Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay. Growth Horm. IGF Res. 11 (2001) 117-127
13. Chen J.W., et al. Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J. Clin. Endocrinol. Metab. 90 (2005) 366-371
14. Furstenberger G., and Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol. 3 (2002) 298-302
15. Pollak M.N., et al. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
16. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19 (2000) 5574-5581
17. Desbois-Mouthon C., et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20 (2001) 252-259
18. Sachdev D., and Yee D. The IGF system and breast cancer. Endocr. Relat. Cancer 8 (2001) 197-209
19. Kaklamani V.G., et al. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J. Clin. Oncol. 17 (1999) 813-817
20. Schoen R.E., et al. Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 581-586
21. Allen N.E., et al. Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 14 (2003) 65-74
22. Chang S., et al. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 758-766
23. Goodwin P.J., et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res. Treat. 74 (2002) 65-76
24. Colangelo L.A., et al. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 385-391
25. Amling C.L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J. Clin. Oncol. 22 (2004) 439-445
26. Lindblad P., et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 42 (1999) 107-112
27. Huxley R., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br. J. Cancer 92 (2005) 2076-2083
28. Larsson S.C., et al. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl. Cancer Inst. 97 (2005) 1679-1687
29. Wolf I., et al. Diabetes mellitus and breast cancer. Lancet Oncol. 6 (2005) 103-111
30. Renehan A.G., and Shalet S.M. Diabetes, insulin therapy, and colorectal cancer. BMJ 330 (2005) 551-552
31. Chan J.M., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-566
32. Renehan A.G., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
33. Morris J.K., et al. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br. J. Cancer 95 (2006) 112-117
34. Renehan A.G., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr. Relat. Cancer 13 (2006) 273-278
35. Renehan A.G., et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm. Metab. Res. 35 (2003) 712-725
36. Li B.D., et al. Free insulin-like growth factor-I and breast cancer risk. Int. J. Cancer 91 (2001) 736-739
37. Janssen J.A., et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J. Clin. Endocrinol. Metab. 89 (2004) 4391-4396
38. Kaaks R., et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 13 (2002) 307-316
39. Keinan-Boker L., et al. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int. J. Cancer 106 (2003) 90-95
40. Krajcik R.A., et al. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 1566-1573
41. Renehan A.G., et al. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br. J. Cancer 83 (2000) 1344-1350
42. Bordone L., and Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev. Mol. Cell Biol. 6 (2005) 298-305
43. Sell C. Caloric restriction and insulin-like growth factors in aging and cancer. Horm. Metab. Res. 35 (2003) 705-711
44. Tran T.T., et al. Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 47-56
45. Koohestani N., et al. Aberrant crypt focus promotion and glucose intolerance: correlation in the rat across diets differing in fat, n-3 fatty acids and energy. Carcinogenesis 19 (1998) 1679-1684
46. Cowey S.L., et al. Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression. Cancer 103 (2005) 2643-2653
47. Wu Y., et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 62 (2002) 1030-1035
48. Wu Y., et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 63 (2003) 4384-4388
49. Yakar S., et al. Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110 (2002) 771-781
50. Komninou D., et al. Insulin resistance and its contribution to colon carcinogenesis. Exp. Biol. Med. (Maywood) 228 (2003) 396-405
51. Morita T., et al. The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac. J. Cancer Prev. 6 (2005) 485-489
52. Furberg A.S., et al. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J. Natl. Cancer Inst. 96 (2004) 1152-1160
53. Facchini F.S., et al. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 86 (2001) 3574-3578
54. Flototto T., et al. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Horm. Metab. Res. 33 (2001) 451-457
55. Key T., et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 94 (2002) 606-616
56. Key T.J., et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst. 95 (2003) 1218-1226
57. Rinaldi S., et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: A study within the EPIC cohort. Int. J. Cancer 118 (2006) 2832-2839
58. Leung K.C., et al. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85 (2000) 4712-4720
59. Sandhu M.S., et al. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J. Natl. Cancer Inst. 94 (2002) 972-980
60. Bray G.A. The underlying basis for obesity: relationship to cancer. J. Nutr. 132 11 Suppl (2002) 3451s-3455s
61. Rose D.P., et al. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes. Rev. 5 (2004) 153-165
62. FitzGerald A.J., et al. Leptin, cell proliferation and crypt fission in the gastrointestinal tract of intravenously fed rats. Cell Prolif. 38 (2005) 25-33
63. Brakenhielm E., et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2476-2481
64. Erlinger T.P., et al. C-reactive protein and the risk of incident colorectal cancer. J. Am. Med. Assoc. 291 (2004) 585-590
65. Bruce W.R., et al. Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr. Cancer 37 (2000) 19-26
66. Cai, D. et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11 (2), 183-190. Epub 2005 Jan 2030
67. Grommes C., et al. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5 (2004) 419-429
68. Dormandy J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
69. Bang P., et al. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J. Clin. Endocrinol. Metab. 78 (1994) 1119-1127
70. Lukanova A., et al. Nonlinear relationship of insulin-like growth factor (IGF)-I and IGF-I/IGF-binding protein-3 ratio with indices of adiposity and plasma insulin concentrations (Sweden). Cancer Causes Control 13 (2002) 509-516